Characterization of Circulating Immune Cells and Correlation with Tie2/Angiopoietins Level in Well Differentiated Neuroendocrine Gastroenteropancreatic Tumors: a Cross-sectional Analysis

Overview

Journal Endocrine

Specialty Endocrinology

Date 2022 Dec 12

PMID 36509928

Authors

F Sesti

G Puliani

T Feola

F Campolo

F Sciarra

V Hasenmajer

A Lenzi

A Faggiano

A M Isidori

M A Venneri

E Giannetta

Affiliations

Soon will be listed here.

Abstract

Purpose: The immune environment represents a new, but little explored, tool for understanding neuroendocrine neoplasms (NENs) behavior. An immunosuppressed microenvironment is hypothesized to promote NENs progression. A missing profiling of circulating leukocyte and peripheral blood mononuclear cells (PBMCs) subpopulations would open new perspectives in the still limited diagnostic-therapeutic management of NENs.

Methods: A cross-sectional case-control pilot study was performed recruiting 30 consecutive subjects: 15 patients naïve to treatment, with histologically proven gastroenteropancreatic (GEP) neuroendocrine tumors (NETs) and 15 healthy controls, matched for age and sex. PBMCs subpopulations were studied by flow cytometry. Soluble Tie2 (sTie2), Angiopoietin-1 (Ang-1), Angiopoietin-2 (Ang-2) were evaluated by ELISA.

Results: Immune cell profiling revealed a significant lower CD3CD56 natural killer (NK) cell count in NETs vs controls (p = 0.04). NK subset analysis showed a reduced relative count of CD56CD16 NK cells (p =0.002) in NETs vs controls. Patients with NET showed a higher percentage of CD14CD16 non-classical monocytes (p = 0.01), and a lower percentage of CD14CD16 intermediate monocytes (p = 0.04). A decrease in percentage (p = 0.004) of CD4 T-helper lymphocytes was found in NET patients. Evaluation of cellular and serum angiopoietin pathway mediators revealed in NET patients a higher relative count of Tie2-expressing monocytes (TEMs) (p < 0.001), and high levels of Ang-1 (p = 0.003) and Ang-2 (p = 0.002).

Conclusions: Patients with GEP-NET presented an immunosuppressed environment characterized by a low count of cytotoxic NK cells, a high count of anti-inflammatory non-classical monocytes, and a low count of T-helper lymphocytes. Higher levels of TEMs and angiopoietins suggest a crosstalk between innate immunity and angiogenic pathways in NETs.

Citing Articles

Circulating Natural Killer Cells as Prognostic Value for Non-Small-Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: Correlation with Sarcopenia.

Tenuta M, Pandozzi C, Sciarra F, Campolo F, Gelibter A, Sirgiovanni G Cancers (Basel). 2023; 15(14).

PMID: 37509255 PMC: 10377538. DOI: 10.3390/cancers15143592.

Association between Biomarkers (VEGF-R2, VEGF-R3, VCAM-1) and Treatment Duration in Patients with Neuroendocrine Tumors Receiving Therapy with First-Generation Somatostatin Analogues.

Rosiek V, Janas K, Kos-Kudla B Biomedicines. 2023; 11(3).

PMID: 36979820 PMC: 10044914. DOI: 10.3390/biomedicines11030842.

References

Cives M, Strosberg J . Gastroenteropancreatic Neuroendocrine Tumors. CA Cancer J Clin. 2018; 68(6):471-487. DOI: 10.3322/caac.21493. View

Bartolomei M, Berruti A, Falconi M, Fazio N, Ferone D, Lastoria S . Clinical Management of Neuroendocrine Neoplasms in Clinical Practice: A Formal Consensus Exercise. Cancers (Basel). 2022; 14(10). PMC: 9140035. DOI: 10.3390/cancers14102501. View

Gajewski T, Schreiber H, Fu Y . Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013; 14(10):1014-22. PMC: 4118725. DOI: 10.1038/ni.2703. View

Hinshaw D, Shevde L . The Tumor Microenvironment Innately Modulates Cancer Progression. Cancer Res. 2019; 79(18):4557-4566. PMC: 6744958. DOI: 10.1158/0008-5472.CAN-18-3962. View

Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K . Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet. 2000; 356(9244):1795-9. DOI: 10.1016/S0140-6736(00)03231-1. View

Venneri M, de Palma M, Ponzoni M, Pucci F, Scielzo C, Zonari E . Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. Blood. 2007; 109(12):5276-85. DOI: 10.1182/blood-2006-10-053504. View

Cives M, Pelle E, Quaresmini D, Rizzo F, Tucci M, Silvestris F . The Tumor Microenvironment in Neuroendocrine Tumors: Biology and Therapeutic Implications. Neuroendocrinology. 2019; 109(2):83-99. DOI: 10.1159/000497355. View

de Reuver P, Mehta S, Gill P, Andrici J, Durso L, Clarkson A . Immunoregulatory Forkhead Box Protein p3-Positive Lymphocytes Are Associated with Overall Survival in Patients with Pancreatic Neuroendocrine Tumors. J Am Coll Surg. 2016; 222(3):281-7. DOI: 10.1016/j.jamcollsurg.2015.12.008. View

Milione M, Miceli R, Barretta F, Pellegrinelli A, Spaggiari P, Tagliabue G . Microenvironment and tumor inflammatory features improve prognostic prediction in gastro-entero-pancreatic neuroendocrine neoplasms. J Pathol Clin Res. 2019; 5(4):217-226. PMC: 6817832. DOI: 10.1002/cjp2.135. View

10.

Iwahori K, Shintani Y, Funaki S, Yamamoto Y, Matsumoto M, Yoshida T . Peripheral T cell cytotoxicity predicts T cell function in the tumor microenvironment. Sci Rep. 2019; 9(1):2636. PMC: 6385254. DOI: 10.1038/s41598-019-39345-5. View

11.

Cuny T, de Herder W, Barlier A, Hofland L . Role of the tumor microenvironment in digestive neuroendocrine tumors. Endocr Relat Cancer. 2018; 25(11):R519-R544. DOI: 10.1530/ERC-18-0025. View

12.

Domagala M, Laplagne C, Leveque E, Laurent C, Fournie J, Espinosa E . Cancer Cells Resistance Shaping by Tumor Infiltrating Myeloid Cells. Cancers (Basel). 2021; 13(2). PMC: 7825276. DOI: 10.3390/cancers13020165. View

13.

Jahchan N, Mujal A, Pollack J, Binnewies M, Sriram V, Reyno L . Tuning the Tumor Myeloid Microenvironment to Fight Cancer. Front Immunol. 2019; 10:1611. PMC: 6673698. DOI: 10.3389/fimmu.2019.01611. View

14.

de Palma M, Venneri M, Galli R, Sergi Sergi L, Politi L, Sampaolesi M . Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell. 2005; 8(3):211-26. DOI: 10.1016/j.ccr.2005.08.002. View

15.

Augustin H, Koh G, Thurston G, Alitalo K . Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol. 2009; 10(3):165-77. DOI: 10.1038/nrm2639. View

16.

Viallard C, Larrivee B . Tumor angiogenesis and vascular normalization: alternative therapeutic targets. Angiogenesis. 2017; 20(4):409-426. DOI: 10.1007/s10456-017-9562-9. View

17.

Chakroborty D, Sarkar C, Yu H, Wang J, Liu Z, Dasgupta P . Dopamine stabilizes tumor blood vessels by up-regulating angiopoietin 1 expression in pericytes and Kruppel-like factor-2 expression in tumor endothelial cells. Proc Natl Acad Sci U S A. 2011; 108(51):20730-5. PMC: 3251052. DOI: 10.1073/pnas.1108696108. View

18.

Coffelt S, Tal A, Scholz A, de Palma M, Patel S, Urbich C . Angiopoietin-2 regulates gene expression in TIE2-expressing monocytes and augments their inherent proangiogenic functions. Cancer Res. 2010; 70(13):5270-80. DOI: 10.1158/0008-5472.CAN-10-0012. View

19.

Srirajaskanthan R, Dancey G, Hackshaw A, Luong T, Caplin M, Meyer T . Circulating angiopoietin-2 is elevated in patients with neuroendocrine tumours and correlates with disease burden and prognosis. Endocr Relat Cancer. 2009; 16(3):967-76. DOI: 10.1677/ERC-09-0089. View

20.

Figueroa-Vega N, Diaz A, Adrados M, Alvarez-Escola C, Paniagua A, Aragones J . The association of the angiopoietin/Tie-2 system with the development of metastasis and leukocyte migration in neuroendocrine tumors. Endocr Relat Cancer. 2010; 17(4):897-908. DOI: 10.1677/ERC-10-0020. View